Molecular Diagnostics News and Research

RSS

NYU Langone strengthens world-leading GI cancer program with renowned leaders

NYU Langone Health's Perlmutter Cancer Center announces the arrival of acclaimed cancer leaders Anirban Maitra, MD, and Manuel Hidalgo, MD, as co-directors of a new Gastrointestinal (GI) Cancer Center.

5 Sep 2025

AI model advances prediction of microsatellite status in cancer

One in every three people is expected to have cancer in their lifetime, making it a major health concern for mankind.

5 Aug 2025

AI-powered blood test improves early Lyme disease detection

Today at ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), researchers will unveil a blood test developed with the help of artificial intelligence (AI) that identifies Lyme disease sooner and more accurately than the current standard - and that could translate to vastly improved patient outcomes.

28 Jul 2025

Advancing diagnostic accuracy in soft tissue cytopathology through WHO guidelines

Soft tissue cytopathology plays a vital role in the diagnosis and management of soft tissue neoplasms, necessitating a standardized classification system to improve diagnostic accuracy and guide clinical decision-making.

18 Jul 2025

Yourgene Health launches LightBench Discover

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, announces the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing.

15 Jul 2025

Intelligent, Scalable, Precise: How n6 Is Transforming NGS Library Prep

In this interview, the team at n6 discusses their groundbreaking iconPCR thermocycler and its impact on laboratory automation, NGS data quality, and real-time control in life sciences.

From n6 7 Jul 2025

Beetle-inspired tuberculosis testing device offers accurate detection for people with HIV

Current tuberculosis infection tests struggle to detect the disease in those with HIV. A common co-infection, HIV can hide TB from traditional tests by eliminating the immune cells relied upon to sound the alarm.

27 Jun 2025

New molecular imaging agent shows high accuracy in detecting liver cancer

A novel molecular imaging agent targeting glypican-3 (GPC3) has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter, according to results from a pilot clinical study.

23 Jun 2025

Machine learning boosts accuracy of point-of-care disease detection

What if people could detect cancer and other diseases with the same speed and ease of a pregnancy test or blood glucose meter? Researchers at the Carl R. Woese Institute for Genomic Biology are a step closer to realizing this goal by integrating machine learning-based analysis into point-of-care biosensing technologies.

17 Jun 2025

New nanopore sequencing assay advances fragile X syndrome carrier screening

Researchers have developed an innovative new nanopore sequencing assay to identify carriers of fragile X syndrome (FXS), the leading cause of monogenic autism spectrum disorder and inherited intellectual disabilities.

12 Jun 2025

Diagnostics.ai launches fully-transparent machine learning platform for real-time PCR diagnostics

As the May 26th CE-IVDR compliance deadline comes into effect, Diagnostics.ai launches the industry's first fully-transparent machine learning platform for clinical real-time PCR diagnostics – demonstrating exactly how each result was achieved, a first for molecular-testing machine learning.

31 May 2025

Building Bridges to Scalable Allogeneic Cell Therapy

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and large-scale manufacturing for allogeneic cell therapies.

From Hanson Wade Group - 7th Allogeneic Cell Therapies Summit 27 May 2025

Liquid biopsy advances precision medicine in gynecological cancers

A landmark review, now published in the Journal of Experimental & Clinical Cancer Research, offers a sweeping and authoritative synthesis on the use of liquid biopsy in gynecological oncology placing this emerging tool at the forefront of precision medicine for women.

16 May 2025

Blood-based biomarkers predict therapy failure in prostate cancer patients

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients.

12 May 2025

Breakthrough in labeling TB glycans could lead to faster diagnosis

Tuberculosis, the world's deadliest infectious disease, is estimated to infect around 10 million people each year, and kills more than 1 million annually. Once established in the lungs, the bacteria's thick cell wall helps it to fight off the host immune system.

5 May 2025

FOXR2 activation found in multiple pediatric brain tumor types

Physicians classify brain tumors and determine treatment options, in part, by the genes they express. According to World Health Organization standards, the abnormal activation of oncogene FOXR2 only occurs in central nervous system (CNS) neuroblastoma, but that may not be true.

16 Apr 2025

New enzyme family enables targeted cuts in single-stranded DNA

An INRS team discovers a new family of enzymes capable of inducing targeted cuts in single-stranded DNA .

16 Apr 2025

Multiple myeloma care improved using innovative optical genome mapping

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma.

15 Apr 2025

Understanding the complex spectrum of Castleman disease

Castleman disease (CD) is a rare, non-clonal lymphoproliferative disorder that manifests with a wide range of histologic and clinical features.

11 Apr 2025

Source Bioscience acquires Cambridge Clinical Laboratories

Source BioScience UK Ltd, an industry-leading provider of genomic services and histopathology diagnostics, today announced it had completed the acquisition of Cambridge Clinical Laboratories (CCL), a leading Cambridge-based provider of clinical, personalized healthcare testing services.

10 Apr 2025